https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC

Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC

Neladalkib enters phase 3 trials, targeting advanced ALK-positive NSCLC, promising improved outcomes for TKI-naïve patients with brain metastases.

administrator

Related Articles